Literature DB >> 11504596

Newer antiepileptic drugs: advantages and disadvantages.

S J Wallace1.   

Abstract

The choice of an antiepileptic drug depends firstly on its efficacy in specific seizure types and epilepsies. However, it is imperative to consider whether possible adverse events will outweigh any benefits. The advantages and disadvantages of vigabatrin, lamotrigine, gabapentin, topiramate, tiagabine and felbamate are considered in some detail, and oxcarbazepine, stiripentol, remacemide, zonisamide and levetiracetam more briefly. Vigabatrin is effective for partial seizures and infantile spasms, but visual field defects are limiting its use. Lamotrigine has a wide spectrum, needs to be prescribed with care. Gabapentin is unlikely to cause adverse effects, but has relatively poor efficacy. Topiramate is widely effective, but can be poorly tolerated. Tiagabine is relatively untried in childhood epilepsies. The use of felbamate is restricted to severe refractory epilepsies. Stiripentol can be effective in severe myoclonic epilepsy in infancy. Zonisamide has a special place in the progressive myoclonus epilepsies. Levetiracetam, remacemide and oxcarbazepine have been used mainly for partial seizures: further studies of their roles in other circumstances are required.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11504596     DOI: 10.1016/s0387-7604(01)00230-3

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  5 in total

1.  Differential effects of topiramate in patients with traumatic brain injury and obesity--a case series.

Authors:  Ornah T Dolberg; Gaby Barkai; Yigal Gross; Shaul Schreiber
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

2.  Myoclonus.

Authors:  Melissa J Nirenberg; Steven J Frucht
Journal:  Curr Treat Options Neurol       Date:  2005-05       Impact factor: 3.598

Review 3.  Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.

Authors:  Ravi Rajmohan; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 4.  Does oxcarbazepine warrant therapeutic drug monitoring? A critical review.

Authors:  Penny Bring; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 5.  Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development.

Authors:  Abdul Wahab
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.